Navigation Links
Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo
Date:3/13/2008

Patented cathode materials result in longer-lasting, safer batteries for

cars, phones, computers

ARGONNE, Ill., March 13 /PRNewswire/ -- The U.S. Department of Energy's (DOE) Argonne National Laboratory and Toda Kogyo Corp. (Toda) of Japan have reached a world-wide licensing agreement for the commercial production and sales of Argonne's patented composite cathode materials for lithium-ion batteries, which result in longer-lasting, safer batteries for hybrid-electric vehicles, cell phones, laptop computers and other applications.

"Our agreement with Toda Kogyo is an important step toward bringing to market key advanced lithium-ion battery technologies that are being developed here at Argonne with funding from the U.S. Department of Energy," Gary Henriksen, Manager of the Electrochemical Energy Storage Department at Argonne, said. "The technologies being licensed will enhance the performance, life and inherent safety of lithium-ion cells compared to those that employ the cobalt-based cathode technology that has dominated the market since the introduction of lithium-ion batteries in 1990."

The family of structurally integrated composite cathode materials being licensed utilizes a new combination of lithium/manganese mixed metal oxides in a revolutionary materials-design approach to extend the time between charges, increase calendar life and improve lithium-ion cell safety.

The new cathode materials are comprised of a composite matrix using an inherently stable inactive lithium-metal oxide that is integrated with a highly active form of another lithium-metal oxide component. This composite allows for greater levels of lithium to be utilized, while reducing oxygen-induced side reactions at the electrode surface that limit cell life and safety. The enhanced stability of these materials allows the system to be charged to higher voltages, leading to a significantly higher energy storage capacity than currently ava
'/>"/>

SOURCE Argonne National Laboratory
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EaglePicher Technologies Receives Battery Power Products and Technologys First Annual Innova Award
2. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
3. New nanotechnology television series does sweat the small stuff
4. A Communitys Fight to Preserve its Historical and Rural Culture in Virginia: Biotechnology CEO Gets Involved
5. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee
6. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
7. Biotechnology Leader to Exhibit at Upcoming Trade Show
8. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
9. New Books on Best Practices in Biotechnology Business Development and Biotechnology Education
10. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
11. CT Laser Mammography Technology to be Featured at European Congress of Radiology
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5